Vline Pharmachem Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 24-10-2024
- Paid Up Capital ₹ 5.00 Cr
as on 24-10-2024
- Company Age 11 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 12.00 Cr
as on 24-10-2024
- Revenue -83.23%
(FY 2023)
- Profit 55.99%
(FY 2023)
- Ebitda 63.74%
(FY 2023)
- Net Worth -8.92%
(FY 2023)
- Total Assets 13.65%
(FY 2023)
About Vline Pharmachem
The Corporate was formerly known as Vline Agri And Pharmachem Private Limited. The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 5.00 Cr.
The company currently has active open charges totaling ₹12.00 Cr.
Venkata Isukapally and Kanakadurga Bhavani serve as directors at the Company.
- CIN/LLPIN
U24301TG2013PTC087124
- Company No.
087124
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Apr 2013
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Vline Pharmachem Private Limited offer?
Vline Pharmachem Private Limited offers a wide range of products and services, including Cardiovascular Drugs & Medication, Anticoagulant and Antiplatelet Drugs.
Who are the key members and board of directors at Vline Pharmachem?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Venkata Isukapally  | Managing Director | 20-Apr-2013 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Kanakadurga Bhavani | Director | 20-Dec-2017 | Current |
Financial Performance of Vline Pharmachem.
Vline Pharmachem Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 83.23% decrease. The company also saw a substantial improvement in profitability, with a 55.99% increase in profit. The company's net worth dipped by a decrease of 8.92%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Vline Pharmachem?
In 2023, Vline Pharmachem had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Wernher Aerospace Technologies Private LimitedActive 6 years 22 daysVenkata Isukapally and Kanakadurga Bhavani are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 25 Oct 2021 | ₹12.00 Cr | Open |
How Many Employees Work at Vline Pharmachem?
Unlock and access historical data on people associated with Vline Pharmachem, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vline Pharmachem, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vline Pharmachem's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
